2017 Emerging Trends Conference: Emerging Trends in Non-Alcoholic Fatty Liver Disease

5 (2 votes)

Recorded On: 03/19/2017

The 2017 Emerging Trends Conference will spearhead a development strategy to disseminate new knowledge and treatment options in NAFLD. Major advances in the epidemiology, natural history, pathogenesis and diagnostic modalities have been uncovered although no established treatment has been approved. By facilitating new and exciting translational and therapeutic research in NAFLD, collaborations among clinicians, industry, academic institutions, and public health agencies will be well equipped to deal with this epidemic that threatens our quality of life.

Zobair M. Younossi

Zobair M Younossi is the President of Inova Medicine as well as Professor and Chairman of the Department of Medicine at Inova Fairfax Medical Campus, Falls Church, Virginia, USA. He is also Chair of Clinical Research, Inova Health System, Falls Church, Virginia. Dr. Younossi earned his medical degree from the University of Rochester School of Medicine and Dentistry (Alpha Omega Alpha 1989) in Rochester, NY, USA. He then completed his residency in internal medicine with a fellowship in gastroenterology and hepatology at Scripps Clinic and Research Foundation in La Jolla, California, USA, while earning his master of public health degree with multiple honours from San Diego State University School of Public Health, San Diego, California, USA. He served as Staff Hepatologist and Senior Researcher at the Cleveland Clinic Foundation, Cleveland, Ohio, USA, before establishing the Canter for Liver Diseases at Inova Fairfax Hospital, which is now renowned for research related to outcomes research in liver disease and clinical, health services and translational research in non-alcoholic fatty liver disease (NAFLD). He has served as Vice President of Research for Inova Health System and currently serves as the Chair of Research for Inova Health System. He also serves as the President and Chairman of the Board of Trustees of the Chronic Liver Disease Foundation (2018-Present) and the Board of Inova Health System Foundation (2011-Present). He was appointed by Governors T Kaine and B McDonnell of Virginia to the Board of Directors of Virginia Biotechnology Research Partnership Authority (2008-2014). He also served Virginia Tobacco & Health Research Repository (VTHRR), Board of Directors, America Heart Association, Mid-Atlantic Affiliate (2010-2012) and Board of the American College of Gastroenterology Institute for Clinical Research & Education (2013-Present). Finally, he has served on multiple committees for American Association for the Study of Liver Diseases, American College of Gastroenterology, American Gastrointestinal Association and George Mason University as well as numerous committees at Inova Fairfax Medical Campus and Inova Health System.

Over the past 3 decades, Dr. Younossi has pioneered research in NAFLD and has been a leader in the field of patient-reported outcomes (PROs), economic assessment and other areas of outcomes research in liver disease. He leads a number of international efforts related to NAFLD and PROs in liver disease though global collaborations, including the Chair of Global NASH Council and the Global Liver and NASH Registries. His research in both NAFLD and outcomes research is highly cited and he a highly sought-after speaker for National and International Scientific meetings. In addition to research and administrative duties, Dr. Younossi has been actively involved in teaching patients (through America Liver Foundation) students (Both medical students and post graduate students), residents and GI/Hepatology fellows. He has also served as Chair, Director or faculty of a number international scientific and CME related courses. He is also the Chair of the Global NASH Council and Global NASH Registry.

Dr. Younossi specializes in hepatology and gastroenterology and has authored over 560 articles, 3 books, 6 journal supplements, over 25 book chapters and over 900 abstracts at the international scientific meetings. He is highly sought-after speaker providing over 430 faculty lectures in national and international meetings. His academic productivity has led to an H-index of 88. Dr.Younossi has also served as the co-editor of Liver International, Associate Editor of J of Hepatology and on the editorial board of a number of important medical journals. He has represented the American Association of Liver Disease and American Gastroenterological Association at different congressional meetings.

Keith D. Lindor

Mary E. McCarthy Rinella

Elisabetta Bugianesi

Components visible upon registration.